EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) have been shown to be effective in the treatment of non‐small cell lung cancer (NSCLC) in patients with mutant EGFR. 2, 3, 4, 5 Although EGFR‐TKIs may lead to initial clinical benefits in most patients with EGFR‐mutated NSCLC, these patients develop acquired resistance to various EGFR‐TKIs.